Indaptus Therapeutics Doses First Patient in Decoy20 and Tislelizumab Combination Trial for Advanced Solid Tumors

Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infectio...

June 03, 2025 | Tuesday | News
Recludix Pharma and Sanofi Advance Oral STAT6 Inhibitor REX-8756 Toward the Clinic for Inflammatory Diseases

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has nominated ...

June 03, 2025 | Tuesday | News
Curevo Enrolls First Patients in Phase 2 Extension Trial of Shingles Vaccine Amezosvatein

Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improve...

June 03, 2025 | Tuesday | News
The Challenge of Modern Drug Discovery

Enter Generative AI: A Paradigm Shift Today, generative AI is changing this equation. Unlike traditional AI that analyzes existing data, generative AI can...

June 03, 2025 | Tuesday | Expert Opinion
Roche’s Itovebi™ Regimen Cuts Risk of Death by Over 30% in PIK3CA-Mutated HR+ Advanced Breast Cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced b...

June 02, 2025 | Monday | News
Kura Oncology’s NDA for Ziftomenib in NPM1-Mutant AML Accepted by FDA with Priority Review

Kura Oncology, Inc.  announced the U.S. Food and Drug Administration (FDA) has accepted Kura’s New Drug Application (NDA) seeking full approva...

June 02, 2025 | Monday | News
Alzamend Doses First Patient in Phase II Trial of AL001, Aiming to Transform Lithium Therapy for Neurological Disorders

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithi...

May 30, 2025 | Friday | News
Candel Therapeutics Secures FDA RMAT Designation for CAN-2409 in Localized Prostate Cancer

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological ...

May 29, 2025 | Thursday | News
SCYNEXIS Resumes Dosing in Phase 3 MARIO Study for Invasive Candidiasis Following FDA Clinical Hold Lift

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infe...

May 29, 2025 | Thursday | News
Why CPOs are vital to getting medical trials over the line

While studies to test the safety and efficacy of new drugs are necessary, their success cannot be guaranteed. In fact, it’s likely that at least 80...

May 28, 2025 | Wednesday | News
Augustine Therapeutics Doses First Patient in Phase I Trial of Novel HDAC6 Inhibitor for Charcot-Marie-Tooth Disease

Augustine Therapeutics NV (“Augustine” or “the Company”), a biotechnology company focused on developing new therapies for neuromu...

May 28, 2025 | Wednesday | News
GlycoEra Secures $130M Series B to Advance First-in-Class IgG4 Protein Degrader Into Clinical Trials

Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support developm...

May 28, 2025 | Wednesday | News
Endurance Bio’s T-168 Selected for SLEIPNIR Trial Platform in Parkinson’s Disease

Endurance Bio Inc., a clinical-stage biotechnology company developing therapies for neurodegenerative and metabolic diseases, today announced that its co...

May 26, 2025 | Monday | News
Invivyd’s PEMGARDA® Added to NCCN Guidelines for B-Cell Lymphomas Amid Ongoing COVID-19 Risk

Invivyd, Inc. announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Net...

May 26, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close